Objectives: Secondary prevention in patients with critical limb ischemia (CLI) is crucial for the reduction of cardiovascular morbidity and mortality. Nonetheless, current recommendations are extrapolated from other high-risk populations due to the lack of CLI dedicated trials. The aim of this study was to report the effects of statin therapy on the outcomes of CLI in the framework of CRITISCH registry.
Methods: CRITISCH is a prospective multicenter registry analyzing the effectiveness of all available treatment strategies in 1200 CLI patients. For the purposes of this analysis, patients were divided into two groups based on the statin administration. Treatment crossovers and nonadherent patients were excluded from analysis. Primary composite end point of this study was amputation-free survival (AFS). Major adverse cardiovascular and cerebral events (MACCE), time to death, and time to major amputation were also analyzed.
Results: Statin therapy was applied in 445 individuals (37%), 371 (31%) patients received no statins, and 384 were excluded from analysis. Patients on statins were more likely to be younger (P < .001) and to have a history of coronary heart disease (P < .001) or previous intervention at the index limb (P < .001). Statin therapy improved the AFS rate (hazard ratio [HR] , 2.21; 95% confidence interval [CI], 1.6-2.9) and survival rate (HR, 2.50; 95% CI, 1.51-4.14; P < .001) but did not reduce the major amputation rate (HR, 0.98; 95% CI, 0.64-1.50). Statin effect on AFS was consistent among diabetic patients (HR, 2.14; 95% CI, 1.43-3.21), patients with chronic kidney disease (HR, 1.90; 95% CI, 1.15-3.13), and individuals aged >75 years (HR, 2.51; 95% CI, 1.66-3.78). Statin administration was associated with improved AFS in patients treated with antiplatelet agents (HR, 1.57; 95% CI, 1.00-2.45; P ¼ .049) and patients who did not receive antiplatelet medication (HR, 3.81; 95% CI, ; P ¼ .001). Statins improved the AFS after both endovascular (HR, 1.97; 95% CI, 1.32-2.93; P ¼ .001) and bypass revascularization (HR, 2.65; 95% CI, 1.46-4.81; P ¼ .001). A higher rate of MACCE was observed among patients not on statins (odds ratio, 2.46; 95% CI, 1. 44-4.26) .
Conclusions: Statin therapy in CLI patients is associated with increased AFS and lower rates of mortality and MACCE, without improving, however, the salvage rates of the affected limb. Objectives: Infrapopliteal angioplasty continues to be widely performed with minimal evidence to guide practice. Endovascular device selection is contentious, and there is even uncertainty over which artery to treat for optimum reperfusion. Direct reperfusion (DR) targets the artery supplying the ischemic tissue. Indirect reperfusion (IR) targets an artery supplying collaterals to the ischemic area. Our unit practice for the last 8 years has been to attempt to open all tibial arteries at the time of angioplasty. When successful, this results in both direct and indirect, or combined reperfusion (CR). The aim was to review the outcomes of CR and compare them with DR or IR alone.
Methods: An 8-year retrospective review from a single unit of all infrapopliteal angioplasties was undertaken. Repeated procedures to treat restenosis or occlusion were excluded unless the patient developed new rest pain or tissue loss over 12 months after documented resolution of symptoms or full healing of previous ulceration. Wound healing, limb salvage, and amputation-free and overall survival data, as well as reintervention rates, were captured for all patients. Subgroup analysis for diabetic patients was undertaken. Kaplan-Meier curves are presented for survival outcomes. All odds ratios, hazard ratios (HR), 95% confidence intervals (CI), and P values were corrected for bias introduced by measured confounders, including demographics, comorbidities, preprocedural blood tests, and elements of the Society for Vascular Surgery Threatened Limb Classification System using multivariate analysis. A power calculation based on our group's recent meta-analysis suggested that a sample size of 200 limbs should be sufficient to show a difference in wound healing rates between treatment strategies.
Results: A total of 250 procedures were performed: 22 (9%) were CR; 115 (46%) DR and 113 (45%) IR. Amputation-free survival (HR, 1.99; 95% CI, 1.04-3.81; P ¼ .039) and reintervention and amputation-free survival (HR 2.42; 95% CI, 1.31-4.48; P ¼ .005) were significantly improved in patients undergoing CR compared to IR. Wound healing was similarly affected by reperfusion strategy (odds ratio, 2.84; 95% CI, 1.02-8.12; P ¼ .047). Effects of CR over IR were similar when only diabetic patients were considered.
Conclusions: We present the largest series to date where a combined revascularization strategy was adopted. Combined revascularization is a challenging procedure which can only be achieved in w10% of patients. However, when successful, it results in significant improvements in wound healing and amputation-free survival over simple indirect reperfusion techniques.
Author Disclosures: G. K. Ambler: Nothing to disclose; C. M. Chick: Nothing to disclose; S. Germain: Nothing to disclose; N. Goyal: Nothing to disclose; U. Hanif: Nothing to disclose; A. L. Stimpson: Nothing to disclose; C. P. Twine: Nothing to disclose; B. G. Wardle: Nothing to disclose. Objectives: This study investigated the efficacy and safety of a new paclitaxel-coated balloon catheter in the treatment of stenotic or occluded femoropopliteal arteries. The incidence of restenosis can be reduced by the use of drug-coated balloons. However, dose, coating composition, and technology are decisive for efficacy.
Methods: The study prospectively randomized 200 Chinese patients with peripheral arterial occlusive disease to treatment with new paclitaxel-coated or standard uncoated balloon catheters. The primary end point was angiographic late lumen loss (LLL) at 6 months measured by a blinded core laboratory. Secondary angiographic end points (6 months) and specific clinical end points (1 year) were binary restenosis, anklebrachial index, Rutherford stage, clinically driven target lesion revascularization (TLR), and amputation.
Results: The patient population was 74% male, 66 years old, 31% smokers, and 55% diabetic. They were at Rutherford stage 2 to 5, lesion length was 150 mm, 25% in-stent restenosis, 55% occlusion or partial occlusion, and 20% provisional stenting. LLL at 6 months was available for 89%, clinical follow-up for >95% per group. LLL was 0.05 6 0.73 mm for coated balloons and 1.15 6 0.89 mm for uncoated balloons (P < .001); correspondingly, restenosis rate was 22.5% vs 70.8% (P < .001). After 1 year, the TLR rate was 7.2% vs 39.6% (P < .001). Rutherford class and ankle-brachial index improved more markedly in the coated group (P < .046 and .023, respectively). One major amputation was recorded in the control group. No coating-related adverse events were observed for doses of up to 43 mg paclitaxel/patient. After 24 months, primary patency was 64.6% vs 31.4% and the TLR rate was 13.5% vs 41.1%. There were no significant between-group differences in the rates of death and major amputation.
Conclusions: In this medium-sized trial with long superficial femoral artery lesions, use of paclitaxel-coated balloon catheters markedly improved angiographic and clinical outcome of interventions despite advanced disease in the majority of patients. Objectives: Ultrasmall superparamagnetic particles of iron oxide (USPIO) detect cellular inflammation and tissue-resident macrophages on magnetic resonance imaging (MRI). In patients with abdominal aortic aneurysm (AAA), we assessed whether USPIO-enhanced MRI can predict AAA growth and clinical outcomes.
Methods: In a prospective multicenter open-label imaging cohort study, we recruited 361 patients with AAA (diameter $40 mm) who underwent baseline USPIO-enhanced MRI. Patients were classified according to the presence of USPIO uptake in the wall of the AAA. All participants were monitored with serial ultrasound imaging and clinical follow-up for a minimum of 2 years. The primary end point was the composite of AAA rupture or repair.
Results: During baseline assessment, 19 patients were withdrawn by the attending clinician or at the participant's request. The study population of 342 participants were predominantly male (293 [85%]), with a mean age of 73 6 7 years and AAA diameter of 50 6 8 mm. Mural USPIO uptake was indeterminate in five participants. During a mean follow-up of 1006 6 279 days, there were 17 (5.0%) AAA ruptures, 126 (36.8%) AAA repairs, and 48 (14.0%) deaths. Compared to those without uptake, patients with mural USPIO uptake had increased AAA expansion (3.4 6 2.4 vs 2.5 6 2.4 mm/y; difference, 0.8 mm/y; 95% confidence intervals [CI] 0.22-1.39 mm/y; P ¼ .007) and higher rates of AAA rupture or repair (69 of Objectives: Endovenous laser ablation (EVLA) is a recommended first-line treatment for superficial venous incompetence (SVI). However such thermal technique requires tumescent anesthesia, which can be uncomfortable for the patient. Newer nonthermal techniques, such as mechanochemical ablation (MOCA), aim to remove or reduce the need for tumescent and thus reduce pain. This randomized controlled trial compared the two treatments with 6 months' follow-up.
Methods: Patients undergoing ablation for symptomatic primary unilateral SVI were randomized to EVLA or MOCA. Concomitant phlebectomy was performed on symptomatic visible varicosities. Outcomes included intraprocedural and postprocedural pain scores on a 100-mm visual analog scale, clinical severity scores, quality of life measurements, recovery time, and duplex ultrasound assessment. Analysis was performed on an intention-to-treat basis. Data were analyzed using parametric and nonparametric statistical tests as dictated by the distribution of data.
Results: Eighty-two patients were randomized (41 MOCA and 41 EVLA). The mean age was 53 years, and 59% were female. Both groups were well matched at baseline. Patients in the MOCA group experienced significantly less pain during truncal ablation (MOCA median 10 mm (interquartile range, 9-24 mm) vs EVLA median 28 mm (interquartile range, 19-59 mm; P ¼ .01). However this benefit was lost following concomitant phlebectomy, and there was no significant difference in the overall pain scores by the end of the procedure (P ¼ .441). Patients in the MOCA group also experienced less pain during the next six postprocedural days (by 5 to 14 mm; P < .05). There was no significant difference between the groups for either return to work (MOCA: median 7 days [interquartile range, 4-14 days] vs EVLA: median, 6 days [interquartile range, 4-14 days]; P ¼ .812) or return to normal activities (MOCA: median 2 days [interquartile range 1-3 days] vs EVLA: median 3 days [interquartile range 1-7 days]; P ¼ .169). Technical success (MOCA: 92% vs EVLA: 94%), clinical severity scores, and disease-specific quality of life scores were similar between groups at 6 weeks and 6 months. There were no significant complications.
Conclusions: During truncal ablation, MOCA is less painful than EVLA, but this benefit is lost if concomitant phlebectomy is performed. MOCA appears less painful during the first postprocedural week. Both have similar recovery time, clinical improvement, short-term technical success, quality of life improvement, and safety outcomes. Longer follow-up is required.
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